January 12, 2015
Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
Media
January 12, 2015
ONCOS-102 granted US lung cancer orphan drug designation
January 08, 2015
Pulmonx® Acquires Assets of Aeris Therapeutics, Expanding the Company’s Treatment Options for COPD Patients
January 07, 2015
NephroGenex Announces That The European Medicines Agency Supports The Company’s Study Design For Ongoing Trial In Diabetic Nephropathy
January 07, 2015
Report from Aerocrine’s Extraordinary General Meeting
January 07, 2015
Aerocrine Reports Record Sales for the 4th Quarter and Full Year 2014
January 07, 2015
Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington’s Disease With Triheptanoin
January 06, 2015
Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia
December 30, 2014
Orexo issues a SEK 500 million bond loan on the Swedish bond market
December 30, 2014
Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release